Palivizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Palivizumab |
| DrugBank ID | DB00110 |
| Brand Names (EU) | Synagis |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season; children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months; children less than two years of age and with haemodynamically significant
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | benign neoplasm of tongue | 99.94% | DL |
| 2 | epiglottis neoplasm | 99.94% | DL |
| 3 | cervical neuroblastoma | 99.94% | DL |
| 4 | benign neoplasm of hypopharynx | 99.94% | DL |
| 5 | benign neoplasm of floor of mouth | 99.94% | DL |
| 6 | tumor of testis and paratestis | 99.94% | DL |
| 7 | cystic neoplasm | 99.94% | DL |
| 8 | schwannoma of jugular foramen | 99.94% | DL |
| 9 | mesenchymoma | 99.94% | DL |
| 10 | thyroglossal duct cyst | 99.94% | DL |
| 11 | nasal cavity inverting papilloma | 99.94% | DL |
| 12 | inner ear neoplasm | 99.93% | DL |
| 13 | benign neoplasm of buccal mucosa | 99.93% | DL |
| 14 | jugular foramen meningioma | 99.93% | DL |
| 15 | benign neoplasm of nasal cavity | 99.93% | DL |
| 16 | chondroid hamartoma | 99.93% | DL |
| 17 | bronchial adenomas/carcinoids childhood | 99.93% | DL |
| 18 | ductal or ductular proliferation | 99.93% | DL |
| 19 | non-seminomatous lesion | 99.93% | DL |
| 20 | vestibulocochlear nerve neoplasm | 99.93% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.